Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lantern Pharma and NCI expand oncology partnership
The latest move follows the identification of various gene signatures that predict a tumour’s possible response to these drug candidates of Lantern. LP-184 is being analysed as a
The latest move follows the identification of various gene signatures that predict a tumour’s possible response to these drug candidates of Lantern. LP-184 is being analysed as a
The laboratory of Steven Rosenberg, chief of surgery at the NCI, discovered these TCRs. NCI is an institute of the National Institutes of Health (NIH). Neogene’s neoantigen TCR
The collaboration will see the base editing programmes to be evaluated leverage Beam’s in vivo delivery technologies. These technologies use messenger RNA (mRNA) and lipid nanoparticles (LNP) to
As part of the collaboration, the company will use its Deep Learning-Enabled Drug Creation and Bionic Protein non-standard amino acid technologies to create enzymes to meet Merck’s biomanufacturing
A selective JAK inhibitor, Rinvoq is currently being analysed in various immune-mediated inflammatory diseases. Both the submissions are supported by the Phase III SELECT-AXIS 2 (Study 2) clinical
The partnership aims to develop new drugs with predictable manufacturing and clinical behaviour. Under the deal, Amgen will make an upfront investment of $50m for the first five
The latest move follows a collaboration and license agreement signed by the companies in November last year. Sold in the US under the brand name Nurtec ODT, rimegepant
An investigational antibody-drug conjugate (ADC), Teliso-V targets c-Met receptor tyrosine kinase that is overexpressed in tumours that include NSCLC. It is indicated to treat nonsquamous NSCLC patients with
The agreement also includes the lead candidate, OV350, which showed promising in-vitro and in-vivo proof of concept in resistant forms of epilepsy. The early-stage compound directly targets and
The production capacity of ritonavir oral tablets has been expanded to 100 million tablets per year and can also be increased further in future based on the market